Abstract | BACKGROUND AND OBJECTIVE: STUDY DESIGN: In a double-blind study, 250 children from the Czech Republic were randomly assigned to receive 15 microg or 30 microg of OspA vaccine at 0, 1, and 2 months. Serum samples, obtained before vaccination and 1 month after the second and third doses, were analyzed for antiOspA antibody. Solicited and unsolicited symptoms were collected from diary cards. RESULTS: Local pain at the injection site was reported by approximately 76% of the 250 children. Headaches (after 5% to 18% of the injections) and malaise (after 2% to 16% of the injections) were the most frequently reported general symptoms. Local and generalized symptoms were not different between the 15 microg and 30 microg groups, and all symptoms resolved within 4 days. Both doses were highly immunogenic, with the 30 microg dose eliciting higher antibody levels. Seroconversion occurred in 99% of the 250 children. CONCLUSIONS:
|
Authors | H M Feder Jr, J Beran, C Van Hoecke, B Abraham, N De Clercq, C Buscarino, D L Parenti |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 135
Issue 5
Pg. 575-9
(Nov 1999)
ISSN: 0022-3476 [Print] United States |
PMID | 10547245
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antigens, Surface
- Bacterial Outer Membrane Proteins
- Bacterial Vaccines
- Lipoproteins
- OspA protein
|
Topics |
- Adolescent
- Animals
- Antigens, Surface
(immunology)
- Bacterial Outer Membrane Proteins
(immunology)
- Bacterial Vaccines
(administration & dosage)
- Borrelia burgdorferi Group
(immunology)
- Child
- Child, Preschool
- Double-Blind Method
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Immunization Schedule
- Lipoproteins
- Lyme Disease
(epidemiology, immunology, prevention & control)
- Male
- Vaccination
|